Pyridostigmine Bromide 180 MG Extended Release Oral Tablet

INDICATION Pyridostigmine Bromide Extended release Tablets is useful in the treatment of myasthenia gravis.

alvogen, inc.

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] fatigue` `[3] dyspnoea` `[4] nausea` `[5] headache` `[6] pain` `[7] diarrhoea` `[8] off label use` `[9] dizziness` `[10] rash`

3 years ago

OVAL YELLOW 335

HOW SUPPLIED

PYRIDOSTIGMINE BROMIDE Extended release Tablets, 180 mg, are supplied in bottles of 30 tablets, NDC 47781-335-30.

PYRIDOSTIGMINE BROMIDE Extended release Tablets are available as a cream to yellow, capsule-shaped tablet, containing 180 mg

PYRIDOSTIGMINE BROMIDE, debossed “335” on one side and has functional scoring on the other side. Storage Store

PYRIDOSTIGMINE BROMIDE Extended release Tablets at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F) [see USP Controlled Room Temperature]. Keep

PYRIDOSTIGMINE BROMIDE Extended release Tablets in a dry place with the silica gel (desiccant) enclosed. Note: Because of the hygroscopic nature of the

PYRIDOSTIGMINE BROMIDE Extended release Tablets, mottling may occur. This does not affect their efficacy.

More pills like OVAL 335

Related Pills

Trihexyphenidyl Hydrochloride Trihexyphenidyl Hydrochloride 2 MG Oral Tablet

Watson Laboratories, Inc.

Levothyroxine Sodium 0.1 MG Oral Tablet

Sandoz Inc.

suvorexant 20 MG Oral Tablet Belsomra

merck sharp & dohme corp.

Levothyroxine Sodium 0.1 MG Oral Tablet

sandoz inc.

Trihexyphenidyl Hydrochloride 2 MG Oral Tablet

Actavis Pharma, Inc.

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site